Drug Profile
SENTI 101
Alternative Names: Adaptive therapies - Senti Biosciences; RNA-based Synthetic biology-based gene circuits - Senti Biosciences; SENTI 101Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Senti Biosciences
- Class Gene therapies; Immunotherapies; Stem cell therapies
- Mechanism of Action Interleukin-12 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Ovarian cancer; Solid tumours
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Intraperitoneal)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Intraperitoneal)
- 22 Jun 2020 Pharmacodynamics data from a preclinical trial in Solid tumour presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-2020)